VYNE Therapeutics
VYNE
72 hedge funds and large institutions have $64M invested in VYNE Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 34 closing their positions.
815% more call options, than puts
Call options by funds: $366K | Put options by funds: $40K
0.47% less ownership
Funds ownership: 2.44% → 1.97% (-0.47%)
19% less funds holding
Funds holding: 89 → 72 (-17)
32% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 22
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 34
58% less capital invested
Capital invested by funds: $154M → $64M (-$90M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$3.23M |
| 2 |
Millennium Management
New York
|
+$2.87M |
| 3 |
Renaissance Technologies
New York
|
+$1.37M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$931K |
| 5 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
+$880K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$11.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$4.4M |
| 3 |
Axa
Paris,
France
|
-$3.35M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.87M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.61M |
VYNE Hedge Fund Activity: Q2 2021 in Review
72 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q2 2021, worth a combined $64M — down 58% from $154M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of VYNE and 17 opened new positions — a net loss of 17 holders — while 22 trimmed existing stakes and 15 added.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $3.23M. The largest seller was BlackRock, cutting an estimated $11.3M.
- 72 institutional investors held VYNE Therapeutics (VYNE) as of Q2 2021, down from 89 in Q1 2021.
- Funds reported $64M of VYNE Therapeutics stock for Q2 2021, down 58% quarter-over-quarter.
- 17 funds opened new VYNE Therapeutics positions in Q2 2021 and 34 closed out, a net change of -17 holders.
- The largest VYNE Therapeutics buyer in Q2 2021 was 683 Capital Management, an estimated $3.23M added.
- The largest VYNE Therapeutics seller in Q2 2021 was BlackRock, an estimated $11.3M sold.
Based on aggregated 13F filings for Q2 2021.